Related Experiment Videos
Effect of beta-adrenergic blocking agents on mortality rate in patients not revascularized after myocardial
H V Barron1, S Viskin, R J Lundstrom
1Department of Medicine, University of California, San Francisco, USA. barron@ep4.ucsf.edu
Insights
Beta-blocker therapy significantly improves survival in myocardial infarction survivors not undergoing coronary angiography. These findings support current guidelines recommending beta-blockers for all eligible post-infarct patients without contraindications.
Area of Science:
- Cardiology
- Clinical Medicine
- Pharmacotherapy
Background:
- Myocardial infarction (MI) survivors often receive beta-blocker therapy.
- The benefit of beta-blockers may differ based on whether patients undergo coronary angiography and revascularization.
Purpose of the Study:
- To determine if chronic beta-blocker therapy provides greater survival benefit in MI patients who do not undergo coronary angiography compared to those who do.
Main Methods:
- Multivariate analyses were employed to assess the impact of beta-blocker treatment on survival.
- Patient groups were stratified based on whether they underwent coronary angiography post-MI.
Main Results:
- Beta-blocker treatment was a significantly stronger predictor of survival in patients not undergoing coronary angiography (relative risk = 0.38, p = 0.005).
- A significant interaction (p < 0.05) indicated a differential effect of beta-blockers based on catheterization status.
Conclusions:
- Beta-blocker therapy offers a substantial survival advantage for MI survivors managed without coronary angiography.
- Findings support existing recommendations for initiating beta-blockers in all eligible post-MI patients lacking contraindications.
Abstract:
We investigated whether patients who do not undergo coronary angiography and therefore any form of revascularization after a myocardial infarction derive greater benefit from chronic beta-blocker therapy than patients who undergo coronary angiography. With multivariate analyses, treatment with beta-blockers was a much stronger predictor of survival in patients who did not undergo coronary angiography (relative risk = 0.38, p = 0.005) than in those patients who did undergo catheterization (p < 0.05 for interaction). Our findings provide direct support for the recommendation by the American College of Cardiology/American Heart Association task force that beta-blocker therapy should be initiated for all infarct survivors who do not undergo revascularization and who have no contraindications.